The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

BioNTech (NASDAQ:BNTX – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Monday, March 10th. Analysts expect the company to announce earnings of $0.38 per ...

In a report released yesterday, Harry Gillis from Berenberg Bank maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

German biotech major BioNTech (Nasdaq: BNTX) has suffered a blow as it seeks to add new revenue streams beyond its COVID-19 ...

The US Patent Trial and Appeal Board handed a massive victory to Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) on Wednesday, ...

European equities traded in the US as American depositary receipts were tracking lower late Thursday morning, declining 0.61% to 1,444.24 on the S&P Europe Select ADR Index. From continental Europe, ...

FDA nominee Marty Makary pledges to review the cancellation of a key flu vaccine meeting, addressing concerns over ...

The earnings docket features key quarterly reports from American Eagle (AEO), BioNTech (BNTX), Dick's Sporting Goods (DKS), ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Semtech (NASDAQ:SMTC – Get Free Report) is anticipated to release its earnings data after the market closes on Thursday, ...

The FDA has ordered BioNTech to immediately halt its Phase I/II trial of malaria vaccine candidate BNT165e, pending changes.